Burosumab, a treatment for X-linked hypophosphatemia, a heritable form of rickets, from Ultragenyx Pharmaceutical and Kyowa Hakko Kirin International was accepted for priority review by the FDA.
FDA accepts biologics application for rickets treatment
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.